DENV Without Warning SignsDENV with Warning SignsSevere DengueHealthy Controls Group - Age and Sex-matched
Investigational drug(s) / intervention(s)
Infection and no infection
Infection and no infection: No intervention apart from the dengue infection
Study summary
The goal of this observational study is to identify biomarkers and host factors associated with dengue severity in patients from dengue-endemic regions. The main question it aims to answer is:
Can multi-omics approaches predict disease severity and identify key factors contributing to severe dengue infections?
Participants will include individuals with dengue infection, and the study will analyze their blood samples using multi-omics techniques to uncover host immune responses, disease pathogenesis, and cellular pathway interactions. The study will also assess the role of primary and secondary infections, virus serotypes, and immunological factors in disease progression. Findings aim to support disease management, improve severity prediction, and identify potential therapeutic targets to prevent severe outcomes.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
Group 1: Dengue without warning signs Patients presenting with the following symptoms confirmed positive for dengue infection by lab diagnosis by anti-dengue IgM or NS1 ELISA will be recruited for the study under this cohort.
Symptoms will be fever along with at least two of the following -
* Myalgia, arthralgia
* Nausea and/or vomiting
* Rashes
* Leukopenia Group 2: DENV with warning signs This cohort will include patients with the above symptoms and any of the following clinical signs.
* Abdominal pain with tenderness
* Persistent vomiting
* Fluid accumulation
* Mucosal bleeding
* Restlessness, lethargy
* Liver enlargement \>2cm
* Laboratory findings: An increase in hematocrit levels and a rapid decrease in platelet count Group 3: Severe dengue
* Severe plasma leakage leads to hypovolemic shock (dengue shock syndrome) and fluid accumulation with respiratory distress.
* Severe bleeding, such as epistaxis, internal bleeding, etc., is evaluated by a clinician.
* Severe organ involvement with any of the following symptoms
* Liver AST or ALT ≥ 1000
* CNS: impaired consciousness
* Heart and other organs failure
Exclusion Criteria:
\-
Primary outcome measure(s)
DISCOVER predictive biomarkers and AI tool for Dengue Severity — From enrollment to the end of hospitalisation at 2 weeks This project aims to identify prognostic plasma protein biomarkers for disease severity in dengue virus (DENV) using data from a clinical cohort in an endemic region experiencing a surge in DENV morbidity and mortality.
It involves developing a novel consensus association-based gene/protein cooperation network to uncover key host factors driving severe disease. Additionally, the project seeks to create AI-driven prognostic tools for predicting DENV severity by integrating patient demographic and clinical data with gene and protein biomarkers, DENV serotyping, and climate information.
Trial sites (2)
Facility
City
Region
Status
Bio Box Guatemala Ong de Investigación, Servicios Y de Medio Ambiente
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.